Blocking Interleukin-4 Receptor α Using Polyethylene Glycol Functionalized Superparamagnetic Iron Oxide Nanocarriers to Inhibit Breast Cancer Cell Proliferation.
- Author:
Abjal Pasha SHAIK
1
;
Asma Sultana SHAIK
;
Ali Al MAJWAL
;
Achraf Al FARAJ
Author Information
- Publication Type:Original Article
- Keywords: Breast neoplasms; Dextran coated superparamagnetic iron oxide; Biomarkers; Tumor; Receptors; Interleukin-4; Drug delivery systems
- MeSH: Antibodies, Blocking; Apoptosis; Biomarkers; Breast Neoplasms*; Breast*; Cell Death; Cell Line; Cell Proliferation*; Cell Survival; Doxorubicin; Drug Delivery Systems; Fluorescence; Fluorescent Antibody Technique; Fluorometry; Humans; In Vitro Techniques; Interleukin-4*; Iron*; Nanoparticles; Neoplasm Metastasis; Oxidative Stress; Polyethylene Glycols*; Polyethylene*; Polymers; Reactive Oxygen Species
- From:Cancer Research and Treatment 2017;49(2):322-329
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The specific targeting of interleukin-4 receptor α (IL4Rα) receptor offers a promising therapeutic approach for inhibition of tumor cell progression in breast cancer patients. In the current study, the in vitro efficacy of superparamagnetic iron oxide nanoparticles conjugated with anti-IL4Rα blocking antibodies (SPION-IL4Rα) via polyethylene glycol polymers was evaluated in 4T1 breast cancer cells. MATERIALS AND METHODS: Cell viability, reactive oxygen species generation, and apoptosis frequency were assessed in vitro in 4T1 cancer cell lines following exposure to SPION-IL4Rα alone or combined with doxorubicin. In addition, immunofluorescence assessments and fluorimetrywere performed to confirm the specific targeting and interaction of the developed nanocarriers with IL4Rα receptors in breast cancer cells. RESULTS: Blocking of IL4Rα receptors caused a significant decrease in cell viability and induced apoptosis in 4T1 cells. In addition, combined treatment with SPION-IL4Rα+doxorubicin caused significant increases in cell death, apoptosis, and oxidative stress compared to either SPION-IL4Rα or doxorubicin alone, indicating the enhanced therapeutic efficacy of this combination. The decrease in fluorescence intensity upon immunofluorescence and fluorimetry assays combined with increased viability and decreased apoptosis following the blocking of IL4Rα receptors confirmed the successful binding of the synthesized nanocarriers to the target sites on murine 4T1 breast cancerous cells. CONCLUSION: These results suggest that SPION-IL4Rα nanocarriers might be used for successfulreduction of tumor growth and inhibition of progression of metastasis in vivo.
